
A drug that can slow the progression of Alzheimer's disease has been blocked for use on the NHS due to cost concerns.
Donanemab was on Wednesday approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as a treatment for people in Britain with mild cognitive impairment, or those in the early stages of Alzheimer’s disease.